Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
Asit Parikh, Brian G. Feagan(Western University), Irving H. Fox(Takeda (United States)), Jing Xu(Kunming Medical University), Timothy Leach(Takeda (United States)), Michael Patella(Millennium Engineering and Integration (United States)), Catherine Scholz(Kura Oncology (United States))
Cited by 80
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k